Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Guardant Health Tops Expectations with Strong Q2 Earnings Boost

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 8/29/2025, 5:41 pm ET | 5 min
Guardant Health Tops Expectations with Strong Q2 Earnings Boost Thumbnail

In this article Last trade Aug, 29 7:32 PM

  • GH+3.72%
    GH - NYSEGuardant Health Inc.
    $66.87+2.40 (+3.72%)
    Volume:  2.86M
    Float:  117.10M
    $64.67Day Low/High$67.51

Guardant Health Inc. stocks have been trading up by 4.58 percent following optimistic investor sentiment from recent impactful news.

Healthcare industry expert:

Analyst sentiment – positive

Market Position & Fundamentals: Guardant Health (GH) demonstrates a challenging financial position with deeply negative margins, including an EBIT margin of -40.2% and a total profit margin of -53.82%. Despite these figures, GH has a robust gross margin of 90.4%, highlighting its ability to control production costs effectively. Revenue generation appears strong, growing by approximately 25% annually over the last five years. Notably, current liquidity ratios are favorable, with a current ratio of 4.1, reflecting solid short-term financial stability. However, significant negative profitability ratios and a deficit in shareholders’ equity signal critical risk factors. In essence, while revenue trajectories and operational efficiency show promise, GH’s fundamental challenge lies in achieving profitability and strengthening its capital structure.

Technical Analysis & Trading Strategy: Recent price action analysis shows Guardant Health’s stock closing at $67.42, indicating bullish momentum over the past week. A strong upward trend is evident from consistent price appreciation, moving from $62 to $67.42. High volume on upward movements suggests strong buying interest. Given these signals, an actionable trading strategy would involve entering a long position at current levels with a target price of $70, utilizing a stop-loss at $64 to mitigate downside risk. This strategy is underpinned by a distinct uptrend and reinforced technical indicators, suggesting a continuation of the bullish momentum.

Catalysts & Outlook: Recent developments at Guardant Health are promising. A 31% revenue growth in Q2 2025, alongside heightened guidance of $915-$925 million, suggests continued momentum in oncology, screening, and biopharma sectors. Strategic partnerships, like the one with James Van Der Beek and the American Cancer Society, enhance brand recognition and healthcare outreach, positioning GH for market expansion. With a price target increase to $63 and outperform ratings from analysts, GH is poised for further growth. The stock’s performance notably surpasses standard healthcare benchmarks. Support around $60 and resistance at $70 define key trading points. Overall, the company’s strategic initiatives and positive analyst sentiment foster an optimistic outlook.

Candlestick Chart

Weekly Update Aug 25 – Aug 29, 2025: On Friday, August 29, 2025 Guardant Health Inc. stock [NASDAQ: GH] is trending up by 4.58%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Guardant Health has reported an impressive financial quarter, with total revenue reaching $232.1M, surpassing the expected $211.3M consensus. This surge marks a 31% increase, chiefly attributed to remarkable performances across the Oncology, Screening, and Biopharma sectors, demonstrating the company’s strategic expansion and effective market positioning. The firm has raised its revenue guidance significantly, forecasting a stellar 24% to 25% growth.

More Breaking News

The fiscal robustness is further reflected in the raised earnings outlook as analysts respond affirmatively. There is heightened market confidence, with Scotiabank and TD Cowen lifting price targets to $60 and $63, respectively, following encouraging second-quarter results. Guardant Health’s gross margins have improved, contributing significantly to its enhanced profitability metrics. The company’s innovations, including 11 new Smart Liquid Biopsy applications, further bolster its competitive edge, promising extensive clinical utility and market expansion.

Conclusion

Guardant Health’s dynamic performance and strategic leverage present a compelling narrative of growth and promise. The company not only reported better-than-expected earnings and revenue growth but also demonstrated strong operational executions with innovative product launches and fruitful partnerships focusing on expanding access to cancer detection technologies. As millionaire penny stock trader and teacher Tim Sykes says, “Preparation plus patience leads to big profits.” These developments translate into a buoyant trader outlook as market confidence receives a significant boost.

Ultimately, Guardant Health’s strategic foresight and industry collaborations position it uniquely within the biopharma landscape, suggesting an evolving trajectory with substantial market impacts ahead. As such, it remains a formidable player, well-poised to harness emerging opportunities and ensure sustainable shareholder value growth in a competitive market milieu.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

In this article (YTD Performance)

  • GH+111.03%
    GH - NYSEGuardant Health Inc.
    $66.87+2.40 (+3.72%)
    Volume:  2.86M
    Float:  117.10M
    $64.67Day Low/High$67.51

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.

notification icon
Subscribe to receive notifications